These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34053399)

  • 21. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parameter estimation following an adaptive treatment selection trial design.
    Luo X; Wu SS; Xiong J
    Biom J; 2010 Dec; 52(6):823-35. PubMed ID: 21154898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drop-the-losers design: normal case.
    Sampson AR; Sill MW
    Biom J; 2005 Jun; 47(3):257-68; discussion 269-81. PubMed ID: 16053251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drop-the-Losers Design: Binomial Case.
    Sill MW; Sampson AR
    Comput Stat Data Anal; 2009 Jan; 53(3):586-595. PubMed ID: 20047003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities.
    Wunder C; Kopp-Schneider A; Edler L
    J Biopharm Stat; 2012; 22(2):294-311. PubMed ID: 22251175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Practical Perspective: Application of the Generalized Approach for Adaptive Design.
    Wang J; Li J; Shu Y; Su X
    Ther Innov Regul Sci; 2020 Jan; 54(1):167-170. PubMed ID: 32008229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment.
    Zhang F; Gou J
    Stat Med; 2023 Dec; 42(28):5229-5246. PubMed ID: 37727983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conditional estimation in two-stage adaptive designs.
    Broberg P; Miller F
    Biometrics; 2017 Sep; 73(3):895-904. PubMed ID: 28099993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.
    Ursino M; Stallard N
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative design and analysis for rare disease drug development.
    Chow SC; Huang Z
    J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.